Amanda Cashin, PhD

Founded in 2013, Wing Venture Capital is a venture capital firm devoted to early-stage, long-term company building in the AI-first technology stack. The body of work of Wings award-winning team spans more than two decades and dozens of successful early-stage companies, 21 of which went on to achieve billion-dollar-plus outcomes following IPOs or acquisitions. Its portfolio companies include Cohesity, AirOps, Gong, Instart Logic, Juvo, Moogsoft, Palerra, Shape Security, and Snowflake.

The Digital Proteome: Unveiling the Final Frontier of Biology Prisma is advancing breakthrough protein sequencing technologies to unveil the true functional drivers of biology and transform human health. Imagine a world where we can resolve every protein within a sample, revealing its identity and quantity with stunning resolution. This is the future Prisma is building with unbiased, single-molecule protein sequencing, a revolutionary approach that analyzes proteins for hypothesis free discovery. Th BioRxiv article in our featured post dives into the core of Prismas elegant protein sequencing technology. Our Universal Recognizer is a single, small molecule dye that binds directly to the N-terminus of proteins and produces a distinct optical fingerprint for each amino acid and post-translational modification. Combined with our cutting-edge, light-based sequencing approach, Prisma generates accurate amino acid sequences to enable unbiased, proteome-scale identification and quantification of proteins at the single-molecule level.

Our passion and mission are one and the same: Build world-beating startups from world-leading science and technology. We are a team of seasoned investors and executives with decades of experience in deploying venture capital to commercialize breakthrough science. Our culture values mutual respect, high performance, curiosity, and humor. Our formal co-investment partnership with Caltech OTTCP’s Seed Fund generates resources for Caltech and ensures alignment with Caltech innovators.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle Park, and New York City. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. For Alexandria, our business has long been about more than real estate. Our mission to advance human health and enhance the quality of people’s lives drives everything we do. We are proud of our position as a key leader and collaborator in the life science ecosystem, where we are able to catalyze and lead the way for positive change to benefit human health and society.